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Abstract
Background: This study aimed to investigate the tolerability and impact of milk of magnesia (MoM) on interfraction
rectal filling during prostate cancer radiotherapy.
Methods: Two groups were retrospectively identified, each consisting of 40 patients with prostate cancer treated with
radiotherapy to prostate+/-seminal vesicles, with daily image-guidance in 78Gy/39fractions/8 weeks. The first-group
followed anti-flatulence diet with MoM started 3-days prior to planning-CT and continued during radiotherapy, while
the second-group followed the same anti-flatulence diet only. The rectum between upper and lower limit of the
clinical target volume (CTV) was delineated on planning-CT and on weekly cone-beam-CT (CBCT). Rectal filling was
assessed by measurement of anterio-posterior diameter of the rectum at the superior and mid levels of CTV, rectal
volume (RV), and average cross-sectional rectal area (CSA; RV/length).
Results: Overall 720 images (80 planning-CT and 640 CBCT images) from 80 patients were analyzed. Using linear
mixed models, and after adjusting for baseline values at the time of planning-CT to test the differences in rectal
dimensions between both groups over the 8-week treatment period, there were no significant differences in RV
(p = 0.4), CSA (p = 0.5), anterio-posterior diameter of rectum at superior (p = 0.4) or mid level of CTV (p = 0.4). In
the non-MoM group; 22.5% of patients had diarrhea compared to 60% in the MoM group, while 40%
discontinued use of MoM by end of radiotherapy.
Conclusion: The addition of MoM to antiflatulence diet did not reduce the interfraction variation in rectal filling
but caused diarrhea in a substantial proportion of patients who then discontinued its use.
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Background
Advances in radiotherapy (RT) technology have permitted
dose escalation in prostate cancer to improve biochemical
control [1]. Precision of RT delivery is an essential compo-
nent to improve outcomes and reduce associated treat-
ment toxicity [2]. Prostate motion is mainly attributable to
changes in rectal volume and shape [3, 4], this has led to
various strategies to reproduce consistent rectal filling and
provide increased accuracy of RT delivery for prostate
cancer.
It has been suggested that using a rectal balloon to
achieve reproducible large rectum is one way to reduce
variations in rectal filling, thereby reducing prostate
motion [5]. Other non-invasive strategies use a rectum-
emptying approach, by means of laxatives, anti-flatulence
diet [6], bowel relaxant [4], probiotics [7], enemas [8],
rectum-emptying tube [9], self evacuation [10], or
combination of these. However the degree of effectiveness
of each of these methods and identification of the most
successful approach is still debatable.
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Since 1997, our institutional policy to reduce rectal
variation consisted of a defined bowel regimen of an
anti-flatulence diet and milk of magnesia (MoM). None-
theless, subsequent studies using magnesium laxatives
failed to show clinically relevant reduction of prostate
motion, with high probability of less laxative intake in
response to diarrhea [11–14]. Subsequently, our institu-
tional practice changed in 2012 to simple dietary advice
(anti-flatulence diet only) without the use of MoM.
Although previous investigation had found no reduction
in intrafraction prostate motion when using our bowel
regimen (with MoM) [12], the efficacy for interfraction
rectal filling was not evaluated. Therefore, in the present
study we investigated the impact of MoM on the inter-




Following institutional research ethics board approval,
two sequential groups of localized prostate cancer pa-
tients treated with volumetric-modulated-arch-therapy
(VMAT) to the prostate +/- seminal vesicles (SV) were
retrospectively identified. Our institutional practice
changed to simple dietary advice without the use of
MoM in 2012, so each group consisted of randomly
chosen 40 consecutive patients treated in 2011 (MoM
cohort) and 2013 (non-MoM cohort). Exclusion criteria
were: prostate cancer patients received palliative or post-
operative radiotherapy or brachytherapy, pelvic lymph
node involvement or distant metastasis, patients with
inflammatory bowel disease or taking laxatives, stool
softeners or anti-flatulence drugs for other indications.
Bowel regimen
All patients participated in a routine educational session
with a radiation therapist regarding the bladder and rec-
tal preparation for radiotherapy planning and treatment.
Patients in the MoM cohort received instructions to fol-
low a bowel regimen which combined an anti-flatulence
diet (Table 1) and MoM, while the non-MoM cohort
followed the same anti-flatulence diet only. All patients
were instructed to start the anti-flatulence diet +/- MoM
three days before the planning CT scan and continue
during RT. The initial once a day (bedtime) dose of
MoM was 30 cm3, adjusted from 15 to 60 cm3 to
achieve a soft bowel movement each morning and
stopped in case of lower gastrointestinal (GI) toxicity
(i.e. diarrhea). Bowel habit description and daily intake
of MoM at baseline and weekly during RT were pro-
spectively documented in the electronic medical record,
as a standard of care. Lower GI toxicity (diarrhea during
RT) was graded according to RTOG acute toxicity scor-
ing criteria.
Radiotherapy
Clinical target volume (CTV) included the prostate;
while base of the SV was included in the CTV if the risk
of SV involvement was > 15% [15]. Planning target vol-
ume (PTV) was created by expansion of the CTV by
10 mm in all directions, except 7 mm posteriorly. RT
was delivered using VMAT to a prescribed dose of 78Gy
in 39 fractions over 8 weeks, using daily prostate-
focused image guidance with cone beam CT (CBCT).
All patients were treated in the supine position, without
rigid immobilization.
Rectal motion assessment
For each patient, the outer rectal wall was delineated as
a solid structure between the upper and lower limits of
the CTV, as changes in rectal diameter at this level
would likely have the greatest influence on prostate pos-
ition. This was performed by a single observer on the
planning CT and on eight randomly selected CBCTs
(one from each week of RT). Rectal filling was assessed
by measurement of the anterio-posterior diameter of the
rectum at the superior and mid levels of CTV, and by
calculation of rectal volume (RV) and the average cross-
sectional rectal area (CSA; defined as the rectal volume
divided by rectal craniocaudal length).
Statistical analyses
Descriptive statistics were used to describe patient and
treatment characteristics. Student’s t-test was used for
comparison of continuous variables. Changes in anterio-
posterior diameter of the rectum at the superior and
mid levels of CTV, RV and CSA between the planning
CT and weekly CBCT were compared between both
groups by repeated measures analysis using linear mixed
models. All tests were two-sided. Statistical analyses
were performed using SAS system (version 9.4; SAS
Institute Inc, Cary, NC).
Results
Patient characteristics
All 80 patients completed the intended course of RT as
planned (78Gy over 39 fractions). The characteristics of
the patients in both groups are summarized in Table 2.
Table 1 Instructions for anti-flatulence diet
Types of food Specific foods to avoid
Vegetables Peas, beans, lentils, broccoli, cauliflower,
brussel sprouts, cabbage, sauerkraut,
cucumber, turnip, rutabaga, onions, garlic
Fruits Apples, bananas, prunes, melons
High-fat foods Pastries, pies, deep-fried foods
Carbonated drinks Soda, beer
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No patients received androgen deprivation treatment.
The 640 CBCTs selected from the 80 patients were
reviewed, and confirmed satisfactory visualisation of the
bladder, prostate and seminal vesicles with good defin-
ition of rectal boundaries between the upper and lower
levels of the CTV.
Interfraction rectal filling characteristics
In each group, a total of 360 images, including 40 plan-
ning CT and 320 CBCT images from the 40 patients
were analyzed. Summary of descriptive statistics of rectal
volume, average CSA, anterioposterior diameter of the
rectum at superior and mid level of CTV in both co-
horts at the time of planning CT are shown in Table 3.
The mean RV for MoM vs. non-MoM groups were
34.1+/- 21.9 vs. 35.5+/- 15.5 cm3, and the average CSA
were 6.3+/-3.7 vs. 6.7+/-2.4 cm2, while the mean anterio-
posterior diameter of the rectum at superior and mid
level of CTV were 3.2+/-1.1 vs. 3.4+/-1 cm and 3.2 +/-1
vs. 3.2+/-0.9 cm respectively. Using linear mixed models,
and after adjusting for baseline values at the time of
planning CT to test the differences in rectal dimensions
between both groups over the 8-week treatment period,
there were no significant differences between MoM vs.
non-MoM group either for RV (p = 0.4), average CSA
(p = 0.5), anterioposterior diameter of the rectum at
superior level of CTV (p = 0.4) or anterioposterior
diameter of rectum at mid level of CTV (p = 0.4) (Fig. 1).
MoM tolerability and gastrointestinal toxicity
In the MoM group, the median volume of MoM taken
by patients was 30 cm3 (range, 15–45 cm3) in the first
week and 15 cm3 (range, 0–30 cm3) in the last week.
The proportion of patients who took MoM decreased
from 100% in the first week to 60% in the last week
(Fig. 2). Acute RTOG lower GI toxicity in MoM vs. non-
MoM groups consisted of G2 diarrhea in 3 patients
(7.5%) vs. 2 patients (5%) and G1 diarrhea in 21 patients
(52.5%) vs. 7 patients (17.5%). In both groups, the onset
of diarrhea was reported in the second week of RT,
however with higher probability among patients who
took MoM (the number of patients who had G1 diarrhea
in the second week of RT in MoM vs. non-MoM group
was 9 [22.5%] vs. 5 [12.5%]).
Discussion
This study demonstrated no significant difference be-
tween the MoM and non-MoM groups in the interfrac-
tion variability of rectal dimensions which could affect
the prostate motion including RV, average CSA, anterio-
posterior diameter of the rectum at superior and mid
level of CTV. Furthermore, G1-2 diarrhea was experi-
enced in 24 (60%) patients in the MoM group compared
to 9 (22.5%) patients who didn’t receive MoM, with 16
(40%) patients discontinuing the use of MoM by the end
of radiation treatment.
Image guided radiotherapy (IGRT) is implemented to
improve the accuracy of treatment delivery, however it
remains difficult to correct for deformation and rotation
of the prostate which is mostly influenced by changes in
rectal filling. Previous studies have shown that changes
in rectal filling can lead to poor outcomes following RT.
[16, 17] Furthermore, maintaining consistent rectal
filling leads to reduction of the required PTV margins
[18], which enables dose escalation of RT to the pros-
tate with probability of better tumour control [19],
without increasing treatment toxicity thereby improv-
ing the therapeutic ratio.






- Median 72 71
- Range 65 - 84 60 - 82
T-category
- T1 22 24
- T2 18 16
Combined Gleason score
- 6 4 5
- 7 36 35
PSA
- Median 8 7
- Range 4 - 17 5 - 17
CTV volume (cm3)
- Median 45 50
- Range 19 - 116 21 - 139
MoM milk of magnesia, CTV clinical target volume
Table 3 Descriptive statistics of rectal measurements at the time of planning
MoM cohort Non-MoM cohort p-value
Mean rectal volume (cm3) 34.8 +/- 20.7 35 +/- 18.7 0.9
Mean average cross sectional area (cm2) 6.5 +/- 3.5 6.5 +/- 2.6 0.9
Mean anterioposterior diameter at superior level of CTV (cm) 3.2 +/- 1 3.2 +/- 0.8 0.9
Mean anterioposterior diameter at mid level of CTV (cm) 3.2 +/- 0.9 3 +/- 0.9 0.3
MoM milk of magnesia, CTV clinical target volume
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The use of laxatives and anti-flatulence diet to reduce
rectal filling variation has been previously investigated.
In a randomised controlled trial (RCT) with 30 prostate
cancer patients, Oat et al. reported that dietary interven-
tion with psyllium (20 g/d, n = 15) didn't significantly
reduce the variability in RV or rectal filling at superior
level of the prostate. It was however, associated with
consistent rectal filling at mid-level of the prostate [20].
In another RCT of prostate cancer patients assigned to
receive magnesium oxide (500 mg twice a day, n = 46) or
placebo (n = 46) during RT and similar to our results,
there was no significant difference in RV between the
treatment arms and magnesium oxide was not effective
in reducing the interfraction rectal filling [14]. Further-
more, several other studies using magnesium laxatives
were unable to show a clinically relevant reduction of
inter- or intra-fractional prostate motion [11–13].
Despite an inability to reduce interfraction prostate
motion, a dietary protocol with laxatives may potentially
decrease the rectal distention related to gas resulting in
better CBCT image quality and facilitating the IGRT
process [11]. On the other hand, tolerability of the laxa-
tive remains an important clinical consideration, with
higher probability of less laxative intake or even anti-
Fig. 1 Interfraction rectal filling assessment in the MoM and non-MoM groups. MoM: milk of magnesia; Control: group of patients who didn't
receive milk of magnesia; Treatment: group of patients who received milk of magnesia; RV: rectal volume; CSA: average cross sectional area;
AP_SUP: Anterioposterior diameter of the rectum at the superior level of clinical target volume; AP_MID: Anterioposterior diamter of the rectum
at the mid level of clinical target volume
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diarrheal use in response to more frequent bowel move-
ment or changing the stool texture [12, 13]. In a RCT of
magnesium oxide (n = 46) vs. placebo (n = 46), patients
in the intervention arm had more frequent grade ≥2
acute GI toxicity (37% vs. 22%) and were more often
prescribed anti-diarrheal medicines during RT (15% vs.
9%) [13]. We had previously reported that the propor-
tion of patients who didn’t take MoM increased from 8%
in the first week to 44% in the last week of RT [12].
Consistently, in the current study, 60% of patients who
took MoM had diarrhea, and 40% discontinued its use
by the end of radiation treatment.
The findings from this study should be interpreted in
context with its methodological limitations. The most
significant limitation is related to its retrospective and
non-randomized nature which may have led to undocu-
mented differences between the cohorts which may have
masked the effect of diet and MoM. Also, compliance
with the antiflatulence diet was not quantified and may
have been different between the two groups, which may
have negated the effect of the diet on interfraction rectal
filling variation. Nonetheless, when considered in con-
text with previous evaluations of this subject, our results
confirm that the addition of MoM to an antiflatulence
diet does not lead to more consistent rectal filling.
Variations in rectal volume and size can influence both
translational prostate motion (which can be corrected
with IGRT), and rotational prostate motion (which is
more difficult to mitigate by current state-of-the-art
technologies). However, rectal filling is not the sole
factor with potential impact in prostate spatial localization,
and different intervention approaches considering altogether
the impact of rectal and bladder filling, patient posi-
tioning and breathing on prostate motion should be
investigated.
Conclusion
The addition of MoM to an antiflatulence diet did not
reduce interfraction variation in rectal filling and may
cause diarrhea resulting in a substantial proportion of
patients discontinuing its use. Simple dietary instruc-
tions appeared to be just as effective at reducing inter-
fraction rectal variability, and MoM should be omitted
from routine use during prostate radiotherapy.
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